personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion- a 6 month follow-up study

Session Details

Session Title: Vascular Diseases II

Session Date/Time: Friday 27/09/2013 | 11:00-12:30

Paper Time: 12:12

Venue: Hall F (Level 2)

First Author: C.Meyer SWITZERLAND

Co Author(s):    G. Spital   F. H?hn   M. Maier   C. Clemens     

Abstract Details

Purpose:

To evaluate the efficacy of intravitreal dexamethasone implants in branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Setting:

Retrospective case series

Methods:

The charts of 102 patients with CME secondary to BRVO (n=54) or CRVO (n=48) were monthly examined over 24 weeks. With progression of the disease (loss of 1 line associated by an increased central retinal thickness (CRT) of 150 um), a reinjection was offered. Additional supplementing sectorial or panretinal laser photocoagulation was considered.

Results:

In BRVO was the BCVA at baseline 0.6 improved to 0.4 after 4 weeks (W), 0.3 8W, 0.4 after 12W, 0.5 16W, 0.4 20W and 0.45 24W. The mean CRT was 559 µm at baseline and decreased to 335 µm 4 weeks, 316 µm 8W, 369 µm 12W, 407 µm 16W, 399 µm 20W, 419 µm 24W. In the CRVO group was the BCVA 0.7 at baseline and improved to 0.4 4W, 0.4 8W, 0.6 12W, 0.6 16W, 0.5 20W and 0.52 24W. The CRT at baseline was 740 µm and decreased to 419 µm 4W, 352 µm 8W, 455 µm 12W, 497 µm 16W, 468 µm 20W and 395 µm 24W. The BCVA improvement was statistically significant better (p<0.05) compared to baseline in both groups at every follow-up visit. The mean CRT maintained significant better compared to baseline in both groups at all follow-up visits. Early re-injection was indicated in BRVO in 40.7 % after 17.5 weeks and in CRVO in 50 % after 17.7. Six eyes (11%) with BRVO received a sectorial laser photocoagulation at 22 weeks. Seven eyes (15%) with CRVO received a panretinal laser photocoagulation after 18 weeks.

Conclusions:

Early re-treatment after 16 weeks instead of 24 weeks was indicated in 50% to stabilize the improved functional and anatomical results.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy